Drug Discovery World

OCTOBER 31, 2023

The drug was developed over eight years by Brian Bigger, Professor of Cell and Gene Therapy at The University of Manchester. Next generation stem cell gene therapy Children with Hunter syndrome have a missing gene, meaning they cannot produce an important enzyme called iduronate-2-sulfatase or IDS.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Rethinking Clinical Trials

SEPTEMBER 22, 2022

The system is used for priority communications from government agencies, hospitals, banks, and others, and allows for rapid delivery of recruitment letters and implementation interventions. The system is used by approximately 5.8 million people, representing more than 95% of the population. Learn more. Read about DANFLU-1.

Trials 130

Trials Cardiology Vaccination Vaccine 130

XTalks

FEBRUARY 27, 2024

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 57

Protein Antibody Engineer Scientist 57

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Pawel Stocki, PhD, Vice President Research, Ossianix, on: ‘Advancing brain shuttle-enabled therapeutics for efficient delivery to cns —translation to primates’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MAY 4, 2021

Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Lorbrena, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Lorbrena (lorlatinib) — In March 2021, Pfizer announced that the U.S.

Vaccination 40

Vaccination Vaccine Production Sales 40